Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 1;180(2):190-197.
doi: 10.1001/jamainternmed.2019.5135.

Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism

Rob F Walker  1 , Neil A Zakai  2   3 , Richard F MacLehose  1 , Logan T Cowan  4 , Terrence J Adam  5 , Alvaro Alonso  6 , Pamela L Lutsey  1
Affiliations

Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism

Rob F Walker et al. JAMA Intern Med. .

Abstract

Importance: Testosterone therapy is increasingly prescribed in patients without a diagnosis of hypogonadism. This therapy may be associated with increased risk of venous thromboembolism (VTE) through several mechanisms, including elevated hematocrit levels, which increase blood viscosity.

Objective: To assess whether short-term testosterone therapy exposure is associated with increased short-term risk of VTE in men with and without evidence of hypogonadism.

Design, setting, and participants: This case-crossover study analyzed data on 39 622 men from the IBM MarketScan Commercial Claims and Encounter Database and the Medicare Supplemental Database from January 1, 2011, to December 31, 2017, with 12 months of follow-up. Men with VTE cases who were free of cancer at baseline and had 12 months of continuous enrollment before the VTE event were identified by International Classification of Diseases codes. Men in the case period were matched with themselves in the control period. Case periods of 6 months, 3 months, and 1 month before the VTE events were defined, with equivalent control periods (6 months, 3 months, and 1 month) in the 6 months before the case period.

Exposures: National drug codes were used to identify billed testosterone therapy prescriptions in the case period (0-6 months before the VTE) and the control period (6-12 months before the VTE).

Main outcomes and measures: The main outcome in this case-only experiment was first VTE event stratified by the presence or absence of hypogonadism.

Results: A total of 39 622 men (mean [SD] age, 57.4 [14.2] years) were enrolled in the study, and 3110 men (7.8%) had evidence of hypogonadism. In age-adjusted models, testosterone therapy use in all case periods was associated with a higher risk of VTE in men with (odds ratio [OR], 2.32; 95% CI, 1.97-2.74) and without (OR, 2.02; 95% CI, 1.47-2.77) hypogonadism. Among men without hypogonadism, the point estimate for testosterone therapy and VTE risk in the 3-month case period was higher for men younger than 65 years (OR, 2.99; 95% CI, 1.91-4.68) than for older men (OR, 1.68; 95% CI, 0.90-3.14), although this interaction was not statistically significant (P = .14).

Conclusions and relevance: Testosterone therapy was associated with an increase in short-term risk for VTE among men with and without hypogonadism, with some evidence that the association was more pronounced among younger men. These findings suggest that caution should be used when prescribing testosterone therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Mr Walker and Drs Adam and Lutsey reported receiving grants from the National Heart, Lung, and Blood Institute, National Institutes of Health during the conduct of the study. Drs Zakai and Alonso reported receiving grants from National Institutes of Health during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Study Design
Schematic of the main (A) and exploratory (B) case-crossover study designs. VTE indicates venous thromboembolism.
See this image and copyright information in PMC

References

    1. Khera M, Adaikan G, Buvat J, et al. . Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(12):1787-1804. doi:10.1016/j.jsxm.2016.10.009 - DOI - PubMed
    1. Wu FC, Tajar A, Beynon JM, et al. ; EMAS Group . Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. doi:10.1056/NEJMoa0911101 - DOI - PubMed
    1. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245-284. doi:10.1111/j.1743-6109.2012.02783.x - DOI - PubMed
    1. Corona G, Dicuio M, Rastrelli G, et al. . Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Investig Med. 2017;65(6):964-973. doi:10.1136/jim-2017-000411 - DOI - PubMed
    1. Rao PK, Boulet SL, Mehta A, et al. . Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. J Urol. 2017;197(4):1121-1126. doi:10.1016/j.juro.2016.10.063 - DOI - PMC - PubMed

Publication types